In contrast to other breast cancer subgroups, where targeted therapies have been developed including several forms of anti-estrogen therapies in hormone receptor positive tumors, or anti-HER2 therapies -nude or loaded antibodies, or small tyrosine kinase inhibitors- in HER2 positive breast cancers (3); the triple negative subtype lacks specific forms of systemic treatment (2). This evidence concerns the gene ERBB2 and breast cancer.